Occam Places Chief Legal Officer at Public Obesity Biotech, Metsera
Metsera (Nasdaq: MTSR) is a clinical-stage biotech focused on developing the next generation of medicines for obesity and metabolic disease. In May 2025, Occam placed Matt Lang as its Chief Legal Officer & Corporate Secretary.
Prior to Metsera, Matt had a multidimensional business career culminating in his service as Chief Business & Legal Officer of the public, clinical-stage cell therapy biotech, Lyell Immunopharma. He came to Lyell from Myovant, where he strategically built the legal and administrative functions of the company and guided the organization through its $2.9B acquisition by Sumitomo Pharma.
A classics major as an undergrad, Matt also received his JD from the University of Pennsylvania.
Related Placements
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.